Premium
Inhibition of bone resorption by 17β‐estradiol in human bone marrow cultures
Author(s) -
Sarma U.,
Edwards M.,
Motoyoshi K.,
Flanagan A. M.
Publication year - 1998
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/(sici)1097-4652(199804)175:1<99::aid-jcp11>3.0.co;2-j
Subject(s) - bone resorption , vitronectin , endocrinology , medicine , bone marrow , osteoporosis , calcitonin , resorption , chemistry , receptor , bone cell , microbiology and biotechnology , biology , integrin
Estrogen deficiency puts individuals at risk of developing osteoporosis because it causes increased bone resorption. However, the mechanism by which this occurs is not known. We have shown, using a recently described two‐phase human bone marrow culture system, that estradiol (17β‐E 2 ) added to phase I results in inhibition of bone resorption by reducing the number of osteoclasts (identified as vitronectin receptor and/or calcitonin receptor‐positive cells) formed in the cultures. The addition of 17β‐E 2 in phase II was without effect, indicating that it does not interfere with the bone resorptive process. 17β‐E 2 down‐regulated mRNA expression and protein synthesis of the membrane form of macrophage colony‐stimulating factor (M‐CSF). 17β‐E 2 did not the alter the expression of the 4.0 kb M‐CSF transcript. However, it increased protein synthesis of the proteoglycan form of M‐CSF, but not the 85 kDa soluble form in the same cultures. Finally, addition of M‐CSF to the cultures reversed the 17β‐E 2 ‐induced inhibitory effect. These observations suggest that regulation of the synthesis of membrane‐bound M‐CSF plays a role in 17β‐E 2 ‐induced inhibition of bone resorption. J. Cell. Physiol. 175:99–108, 1998. © 1998 Wiley‐Liss, Inc.